Search Results - "Isambert, Nicolás"

Pyrano[3,2-c]quinoline−6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds by Camps, Pelayo, Formosa, Xavier, Galdeano, Carles, Muñoz-Torrero, Diego, Ramírez, Lorena, Gómez, Elena, Isambert, Nicolás, Lavilla, Rodolfo, Badia, Albert, Clos, M. Victòria, Bartolini, Manuela, Mancini, Francesca, Andrisano, Vincenza, Arce, Mariana P, Rodríguez-Franco, M. Isabel, Huertas, Óscar, Dafni, Thomai, Luque, F. Javier

“…Two isomeric series of dual binding site acetylcholinesterase (AChE) inhibitors have been designed, synthesized, and tested for their ability to inhibit AChE,…”
Get full text

Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates by Camps, Pelayo, Formosa, Xavier, Galdeano, Carles, Gómez, Tània, Muñoz-Torrero, Diego, Ramírez, Lorena, Viayna, Elisabet, Gómez, Elena, Isambert, Nicolás, Lavilla, Rodolfo, Badia, Albert, Clos, M. Victòria, Bartolini, Manuela, Mancini, Francesca, Andrisano, Vincenza, Bidon-Chanal, Axel, Huertas, Óscar, Dafni, Thomai, Luque, F. Javier

“…Two novel families of dual binding site acetylcholinesterase (AChE) inhibitors have been developed, consisting of a tacrine or 6-chlorotacrine unit as the…”
Get full text

Heterocycles as Key Substrates in Multicomponent Reactions: The Fast Lane towards Molecular Complexity by Isambert, Nicolas, Lavilla, Rodolfo

“…Heterocycles display an intrinsic reactivity which enables rich, versatile and productive transformations. Taking into account their ubiquitous presence in…”
Get full text

Benzimidazolium Salts as Small, Nonpeptidic and BBB-Permeable Human Prolyl Oligopeptidase Inhibitors by Tarragó, Teresa, Masdeu, Carme, Gómez, Elena, Isambert, Nicolás, Lavilla, Rodolfo, Giralt, Ernest

“…Prolyl oligopeptidase (POP) is a cytosolic serine peptidase that hydrolyzes proline‐containing peptides at the carboxy terminus of proline residues. This…”
Get full text

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial by Le Tourneau, Christophe, Dr, Delord, Jean-Pierre, Prof, Gonçalves, Anthony, Prof, Gavoille, Céline, MD, Dubot, Coraline, MD, Isambert, Nicolas, MD, Campone, Mario, Prof, Trédan, Olivier, MD, Massiani, Marie-Ange, MD, Mauborgne, Cécile, MSc, Armanet, Sebastien, MSc, Servant, Nicolas, PhD, Bièche, Ivan, PhD, Bernard, Virginie, PhD, Gentien, David, PhD, Jezequel, Pascal, MD, Attignon, Valéry, PhD, Boyault, Sandrine, PhD, Vincent-Salomon, Anne, MD, Servois, Vincent, MD, Sablin, Marie-Paule, MD, Kamal, Maud, PhD, Paoletti, Xavier, PhD

“…Summary Background Molecularly targeted agents have been reported to have anti-tumour activity for patients whose tumours harbour the matching molecular…”
Get full text

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial by Herbst, Roy S, Prof, Arkenau, Hendrik-Tobias, MD, Santana-Davila, Rafael, MD, Calvo, Emiliano, MD, Paz-Ares, Luis, Prof, Cassier, Philippe A, MD, Bendell, Johanna, MD, Penel, Nicolas, Prof, Krebs, Matthew G, MD, Martin-Liberal, Juan, MD, Isambert, Nicolas, MD, Soriano, Andres, MD, Wermke, Martin, MD, Cultrera, Jennifer, MD, Gao, Ling, PhD, Widau, Ryan C, PhD, Mi, Gu, PhD, Jin, Jin, PhD, Ferry, David, MD, Fuchs, Charles S, Prof, Petrylak, Daniel P, Prof, Chau, Ian, MD

“…SummaryBackgroundPre-clinical and clinical evidence suggests that simultaneous blockade of VEGF receptor-2 (VEGFR-2) and PD-1 or PD-L1 enhances…”
Get full text

Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study by Molassiotis, Alexander, RN, PhD, Aapro, Matti, MD, Dicato, Mario, MD, FRCP, Gascon, Pere, MD, PhD, Novoa, Sylvia A., MD, Isambert, Nicolas, MD, Burke, Thomas A., PhD, Gu, Anna, MD, PhD, Roila, Fausto, MD

“…Abstract Context Demographic, personal, clinical, and behavioral factors predicting chemotherapy-induced nausea and vomiting (CINV) have been assessed in the…”
Get full text

Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study by Toulmonde, Maud, MD, Pulido, Marina, MSc, Ray-Coquard, Isabelle, Prof, Andre, Thierry, Prof, Isambert, Nicolas, MD, Chevreau, Christine, MD, Penel, Nicolas, Prof, Bompas, Emmanuelle, MD, Saada, Esma, MD, Bertucci, François, MD, Lebbe, Celeste, MD, Le Cesne, Axel, MD, Soulie, Patrick, MD, Piperno-Neumann, Sophie, MD, Sweet, Stephen, PhD, Cecchi, Fabiola, PhD, Hembrough, Todd, PhD, Bellera, Carine, PhD, Kind, Michèle, MD, Crombe, Amandine, MD, Lucchesi, Carlo, PhD, Le Loarer, François, MD, Blay, Jean-Yves, Prof, Italiano, Antoine, Prof

“…SummaryBackgroundDesmoid tumours are locally aggressive tumours associated with substantial morbidity. No systemic treatments are approved for this disease,…”
Get full text

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial by Mir, Olivier, MD, Brodowicz, Thomas, MD, Italiano, Antoine, MD, Wallet, Jennifer, MSc, Blay, Jean-Yves, MD, Bertucci, François, MD, Chevreau, Christine, MD, Piperno-Neumann, Sophie, MD, Bompas, Emmanuelle, MD, Salas, Sébastien, MD, Perrin, Christophe, MD, Delcambre, Corinne, MD, Liegl-Atzwanger, Bernadette, MD, Toulmonde, Maud, MD, Dumont, Sarah, MD, Ray-Coquard, Isabelle, MD, Clisant, Stéphanie, PharmD, Taieb, Sophie, MD, Guillemet, Cécile, MD, Rios, Maria, MD, Collard, Olivier, MD, Bozec, Laurence, MD, Cupissol, Didier, MD, Saada-Bouzid, Esma, MD, Lemaignan, Christine, MD, Eisterer, Wolfgang, MD, Isambert, Nicolas, MD, Chaigneau, Loïc, MD, Cesne, Axel Le, MD, Penel, Nicolas, Dr

“…Summary Background Regorafenib is a multikinase inhibitor with proven activity in refractory gastrointestinal stromal tumours and chemotherapy-refractory…”
Get full text

Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors by RUSAKIEWICZ, Sylvie, SEMERARO, Michaela, CHAIGNEAU, Loic, LE BRUN-LY, Valérie, DUBREUIL, Patrice, CREMER, Isabelle, CAIGNARD, Anne, POIRIER-COLAME, Vichnou, CHABA, Kariman, FLAMENT, Caroline, HALAMA, Niels, JÄGER, Dirk, SARABI, Matthieu, EGGERMONT, Alexander, BONVALOT, Sylvie, COMMO, Frédéric, TERRIER, Philippe, OPOLON, Paule, EMILE, Jean-François, COINDRE, Jean-Michel, KROEMER, Guido, CHAPUT, Nathalie, LE CESNE, Axel, DESBOIS, Mélanie, BLAY, Jean-Yves, ZITVOGEL, Laurence, LOCHER, Clara, MENDEZ, Rosa, VIMOND, Nadège, CONCHA, Angel, GARRIDO, Federico, ISAMBERT, Nicolas

“…Cancer immunosurveillance relies on effector/memory tumor-infiltrating CD8(+) T cells with a T-helper cell 1 (TH1) profile. Evidence for a natural killer (NK)…”
Get full text

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial by Mir, Olivier, MD, Cropet, Claire, MSc, Toulmonde, Maud, MD, Cesne, Axel Le, MD, Molimard, Mathieu, Prof, Bompas, Emmanuelle, MD, Cassier, Philippe, MD, Ray-Coquard, Isabelle, Prof, Rios, Maria, MD, Adenis, Antoine, Prof, Italiano, Antoine, MD, Bouché, Olivier, Prof, Chauzit, Emmanuelle, PharmD, Duffaud, Florence, Prof, Bertucci, François, Prof, Isambert, Nicolas, MD, Gautier, Julien, MSc, Blay, Jean-Yves, Prof, Pérol, David, MD

“…Summary Background Gastrointestinal stromal tumours (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract. Imatinib followed by…”
Get full text

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study by PENEL, Nicolas, BINH NGUYEN BUI, ISAMBERT, Nicolas, PEYRADE, Frédéric, CHEVREAU, Christine, BOMPAS, Emmanuelle, BRAIN, Etienne G. C, BLAY, Jean-Yves, BAY, Jacques-Olivier, CUPISSOL, Didier, RAY-COQUARD, Isabelle, PIPERNO-NEUMANN, Sophie, KERBRAT, Pierre, FOURNIER, Charles, TAIEB, Sophie, JIMENEZ, Marta

“…The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma…”
Get full text

Health-related quality of life as an endpoint in oncology phase I trials: a systematic review by Fiteni, Frédéric, Ray, Isabelle Le, Ousmen, Ahmad, Isambert, Nicolas, Anota, Amélie, Bonnetain, Franck

“…Phase I trials aim to identify the recommended dose for further development. Health-related quality of life (HRQoL) could be a complement to the usual National…”
Get full text

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors by Delahaye, Nicolas F, Rusakiewicz, Sylvie, Martins, Isabelle, Ménard, Cédric, Roux, Stephan, Lyonnet, Luc, Paul, Pascale, Sarabi, Matthieu, Chaput, Nathalie, Semeraro, Michaela, Minard-Colin, Véronique, Poirier-Colame, Vichnou, Chaba, Kariman, Flament, Caroline, Baud, Véronique, Authier, Hélène, Kerdine-Römer, Saadia, Pallardy, Marc, Cremer, Isabelle, Peaudecerf, Laetitia, Rocha, Bénédita, Valteau-Couanet, Dominique, Gutierrez, Javier Celis, Nunès, Jacques A, Commo, Frédéric, Bonvalot, Sylvie, Ibrahim, Nicolas, Terrier, Philippe, Opolon, Paule, Bottino, Cristina, Moretta, Alessandro, Tavernier, Jan, Rihet, Pascal, Coindre, Jean-Michel, Blay, Jean-Yves, Isambert, Nicolas, Emile, Jean-François, Vivier, Eric, Lecesne, Axel, Kroemer, Guido, Zitvogel, Laurence

“…Gastrointestinal stromal tumors can respond to imatinib mesylate therapy owing to its inhibitory action on tumor cells as well as off-target effects on NK…”
Get full text

Exosomes in cancer theranostic: Diamonds in the rough by Cordonnier, Marine, Chanteloup, Gaëtan, Isambert, Nicolas, Seigneuric, Renaud, Fumoleau, Pierre, Garrido, Carmen, Gobbo, Jessica

“…During the last 10 years, exosomes, which are small vesicles of 50-200 nm diameter of endosomal origin, have aroused a great interest in the scientific and…”
Get full text

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study by Isambert, Nicolas, Hervieu, Alice, Rébé, Cedric, Hennequin, Audrey, Borg, Christophe, Zanetta, Sylvie, Chevriaux, Angélique, Richard, Corentin, Derangère, Valentin, Limagne, Emeric, Blanc, Julie, Bertaut, Aurélie, Ghiringhelli, François

“…In preclinical models, IL-1β inhibition could enhance the efficacy of fluorouracil (5-FU). In this phase 2 study, we assessed the activity and safety of 5-FU…”
Get full text

Primary cardiac sarcomas: A retrospective study of the French Sarcoma Group by Isambert, Nicolas, Ray-Coquard, Isabelle, Italiano, Antoine, Rios, Maria, Kerbrat, Pierre, Gauthier, Mélanie, Blouet, Aurélien, Chaigneau, Loïc, Duffaud, Florence, Piperno-Neumann, Sophie, Kurtz, Jean-Emmanuel, Girard, Nicolas, Collard, Olivier, Bompas, Emmanuelle, Penel, Nicolas, Bay, Jacques-Olivier, Guillemet, Cécile, Collin, Françoise, Blay, Jean-Yves, Le Cesne, Axel, Thariat, Juliette

“…Abstract Introduction Primary cardiac sarcomas (PCS) are rare tumours of dismal prognosis. Methods Data of 124 patients with PCS referred to institutions of…”
Get full text

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort by Cho, Byoung Chul, Daste, Amaury, Ravaud, Alain, Salas, Sébastien, Isambert, Nicolas, McClay, Edward, Awada, Ahmad, Borel, Christian, Ojalvo, Laureen S, Helwig, Christoph, Rolfe, P Alexander, Gulley, James L, Penel, Nicolas

“…BackgroundWe report the clinical activity and safety of bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of…”
Get full text

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers by Angevin, Eric, Isambert, Nicolas, Trillet-Lenoir, Véronique, You, Benoit, Alexandre, Jérôme, Zalcman, Gérard, Vielh, Philippe, Farace, Françoise, Valleix, Fanny, Podoll, Thomas, Kuramochi, Yu, Miyashita, Itaru, Hosono, Osamu, Dang, Nam H, Ohnuma, Kei, Yamada, Taketo, Kaneko, Yutaro, Morimoto, Chikao

“…Background: YS110 is a humanised IgG1 monoclonal antibody with high affinity to the CD26 antigen. YS110 demonstrated preclinical anti-tumour effects without…”
Get full text

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial by Pautier, Patricia, Dr, Floquet, Anne, MD, Chevreau, Christine, MD, Penel, Nicolas, MD, Guillemet, Cécile, MD, Delcambre, Corinne, MD, Cupissol, Didier, MD, Selle, Frédéric, MD, Isambert, Nicolas, MD, Piperno-Neumann, Sophie, MD, Thyss, Antoine, Prof, Bertucci, François, Prof, Bompas, Emmanuelle, MD, Alexandre, Jerôme, Prof, Collard, Olivier, MD, Lavau-Denes, Sandrine, MD, Soulié, Patrick, MD, Toulmonde, Maud, MD, Le Cesne, Axel, MD, Lacas, Benjamin, MSc, Duffaud, Florence, Prof

“…Summary Background Metastatic leiomyosarcomas of uterine or soft-tissue origin have poor prognosis and moderate chemosensitivity. Trabectedin has shown…”
Get full text